CBD Again Rejected as a Dietary Supplement

By letter dated July 23, 2021, the FDA responded to an application by Charlotte’s Web, Inc. to designate its CBD as a new dietary ingredient (NDI) to be used in a dietary supplement tincture known as “Charlotte’s Web Full Spectrum Hemp Extract.”  The FDA stated that CBD could not be marketed as a dietary supplement or as an NDI because of an existing drug approval for Epidiolex, and thus is subject to the exclusion from the definition of dietary supplement. Because CBD is the active ingredient in the approved drug product, the CBD product could not be marketed as or in a dietary supplement.   The FDA added that it “has concerns about the adequacy of safety evidence” that the company submitted relating to potential liver and reproductive toxicity.

Takeaway: Marketers of CBD products need to take into account the current regulatory status of the ingredient.  With the FDA again rejecting characterization of CBD as a dietary supplement ingredient, caution is urged in making traditional structure/function claims for such products.

Add a comment

Type the following characters: whisky, november, six, hotel, whisky

* Indicates a required field.

Subscribe

Recent Posts

Contributors

Archives

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.